Immune Subtypes of PPGL: Genomic Determinants and Therapeutic Implications

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms with significant hereditary predisposition and metastatic potential for which systemic treatment options remain limited. Although characterized as immunologically inert tumors, emerging evidence reveals a biologically meaningful diversity of immune subtypes whose distribution is tightly coupled to genomic subtype, metabolic phenotype, and clinical behavior. PPGLs are classified into three major transcriptional clusters, pseudohypoxic, kinase signaling, and WNT-altered, each associated with a characteristic tumor microenvironment (TME). Pseudohypoxic tumors, driven by SDHx and related alterations, display immunosuppressive microenvironments enriched in fibroblast-like perivascular cells and shaped by succinate accumulation and HIF-2α-mediated signaling, while kinase signaling tumors preferentially associate with immune-enriched profiles. MAML3 fusion-positive tumors represent a distinct immunological exception, combining adaptive PD-L1 overexpression with CD8+ T cell and NK cell infiltration and a higher predicted neoantigen burden, whose functional relevance remains to be established. Secondary genomic events, particularly ATRX mutations, TERT activation, and somatic copy number alterations, further modulate immune contexture and metastatic risk. Pan-cancer immune classification frameworks identify lymphocyte-depleted subtypes as predominant in PPGLs, with a progressive shift toward greater immunosuppression in metastatic disease. These findings have direct therapeutic implications: the HIF-2α inhibitor belzutifan has demonstrated meaningful activity in pseudohypoxic tumors and may carry immunomodulatory effects, while MAML3 fusion-positive and immune-enriched kinase signaling tumors may represent the subset most amenable to immune checkpoint inhibition. Translating this biological complexity into clinical benefit will require molecularly stratified trials, standardized immune profiling, and expanded international collaborative efforts.

Authors

Institutions

Publication Details

Journal
Endocrine Related Cancer
Published
2026-11-13
DOI
https://doi.org/10.1530/erc-26-0295
Primary Topic
Adrenal and Paraganglionic Tumors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune Subtypes of PPGL: Genomic Determinants and Therapeutic Implications

Mercedes Robledo, Milton Eduardo Salazar-Hidalgo, Alberto Cascón, Ester Arroba
3 links
Endocrine Related Cancer
Adrenal and Paraganglionic Tumors
article

Immune Subtypes of PPGL: Genomic Determinants and Therapeutic Implications

Mercedes Robledo, Milton Eduardo Salazar-Hidalgo, Alberto Cascón, Ester Arroba
article en

Abstract

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms with significant hereditary predisposition and metastatic potential for which systemic treatment options remain limited. Although characterized as immunologically inert tumors, emerging evidence reveals a biologically meaningful diversity of immune subtypes whose distribution is tightly coupled to genomic subtype, metabolic phenotype, and clinical behavior. PPGLs are classified into three major transcriptional clusters, pseudohypoxic, kinase signaling, and WNT-altered, each associated with a characteristic tumor microenvironment (TME). Pseudohypoxic tumors, driven by SDHx and related alterations, display immunosuppressive microenvironments enriched in fibroblast-like perivascular cells and shaped by succinate accumulation and HIF-2α-mediated signaling, while kinase signaling tumors preferentially associate with immune-enriched profiles. MAML3 fusion-positive tumors represent a distinct immunological exception, combining adaptive PD-L1 overexpression with CD8+ T cell and NK cell infiltration and a higher predicted neoantigen burden, whose functional relevance remains to be established. Secondary genomic events, particularly ATRX mutations, TERT activation, and somatic copy number alterations, further modulate immune contexture and metastatic risk. Pan-cancer immune classification frameworks identify lymphocyte-depleted subtypes as predominant in PPGLs, with a progressive shift toward greater immunosuppression in metastatic disease. These findings have direct therapeutic implications: the HIF-2α inhibitor belzutifan has demonstrated meaningful activity in pseudohypoxic tumors and may carry immunomodulatory effects, while MAML3 fusion-positive and immune-enriched kinase signaling tumors may represent the subset most amenable to immune checkpoint inhibition. Translating this biological complexity into clinical benefit will require molecularly stratified trials, standardized immune profiling, and expanded international collaborative efforts.

Endocrine Related Cancer
Instituto de Salud Carlos III (ES), Spanish National Cancer Research Centre (ES), Centre for Biomedical Network Research on Rare Diseases (ES)
Good health and well-being
Adrenal and Paraganglionic Tumors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon